Daina Schmidt Joins Obalon Therapeutics As Vice President, Marketing
SAN DIEGO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces the appointment of Daina Schmidt to Vice President, Marketing. Ms. Schmidt will be responsible for creating and implementing the marketing strategy to increase treatments and brand awareness of the Obalon Balloon System.
“Daina’s proven success leading marketing teams in the consumer health and aesthetic segments provides a strong fit for Obalon,” said Kelly Huang, Ph.D., President and Chief Operating Office of Obalon. “Daina will be instrumental in strengthening our brand as we continue to develop the market for our proprietary gastric balloon weight loss system for individuals with a BMI between 30 to 40 kg/m2.”
“Weight loss can be critical for health and self-esteem and obesity is a major public health concern. I am excited to be part of the Obalon management team where I have an opportunity to help provide innovative solutions to this growing problem,” stated Ms. Schmidt.
Ms. Schmidt brings deep experience in patient-pay categories such as Ophthalmology, Plastic Surgery, and Dermatology. Most recently, Ms. Schmidt was Senior Director of Marketing at Syneron Candela, where she led the launch of Vbeam® Prima. Prior to that she was with Valeant as Sr. Director for Obagi, a position she transitioned to, following Valeant’s acquisition of Bausch + Lomb, where she was the Executive Director of Global Marketing for the cataract business. Ms. Schmidt also held positions at Allergan from 2002 to 2011, including Senior Director of Global Marketing for Allergan’s breast implant business. She holds a Bachelor of Arts degree in Economics from the University of Colorado and an MBA from the University of Michigan.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit .
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics' future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the product research, development and regulatory process and risks. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics' business in general, please refer to Obalon Therapeutics’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 2, 2018, and its current and future periodic reports filed with the Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office:
Media:
Megan Driscoll
EvolveMKD
Office Phone:
